These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 598046)

  • 1. [Clinical effect of fluoxymesterone in the treatment of recurrent and progressive breast neoplasms].
    Takaya O
    Horumon To Rinsho; 1977 Dec; 25(12):1371-84. PubMed ID: 598046
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effect of fluoxymesterone (Halotestin) on progressive breast cancer].
    Yoshida Y; Miura S; Takeuchi S
    Horumon To Rinsho; 1972 Aug; 20(8):655-66. PubMed ID: 4675689
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical evaluation of 1,3-bis(2-chloroethyl)-nitrosourea (BCNU; NSC-409962) with fluoxymesterone (NSC-12165) in the treatment of solid tumors.
    Reyes ES; Talley RW; O'Bryan RM; Gastesi RA
    Cancer Chemother Rep; 1973 Apr; 57(2):225-30. PubMed ID: 4582564
    [No Abstract]   [Full Text] [Related]  

  • 4. 2alpha, 3alpha-epithio-5alpha-androstan-17beta-yl 1-methoxycyclopentyl ether in the treatment of advanced breast cancer: Japanese Cooperative Group of Hormonal Treatment for Breast Cancer.
    Cancer; 1978 Feb; 41(2):758-60. PubMed ID: 343913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sounding board. Waiting for a bus: Does it explain age-dependent differences in response to chemotherapy of early breast cancer?
    Rozencweig M; Zelen M; Von Hoff DD; Muggia FM
    N Engl J Med; 1978 Dec; 299(24):1363-4. PubMed ID: 581394
    [No Abstract]   [Full Text] [Related]  

  • 6. Androgen therapy in the treatment of refractory epithelial ovarian cancer.
    Kavanagh JJ; Wharton JT; Roberts WS
    Cancer Treat Rep; 1987 May; 71(5):537-8. PubMed ID: 3567978
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of tamoxifen dose in advanced breast cancer: a progress report.
    Tormey DC; Simon RM; Lippman ME; Bull JM; Myers CE
    Cancer Treat Rep; 1976 Oct; 60(10):1451-9. PubMed ID: 1021226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Letter: Calusterone (NSC-88536) in advanced breast cancer.
    Falkson G; Falkson HC
    Cancer Treat Rep; 1976 Mar; 60(3):220-1. PubMed ID: 130973
    [No Abstract]   [Full Text] [Related]  

  • 9. Calusterone (NSC-88536): a poor substitute for fluoxy-mesterone (NSC-12165) in the treatment of advanced breast cancer.
    Falkson G; van Dyk JJ; van Eden EB; van der Merwe AM; FALKSON HC
    Cancer Chemother Rep; 1974; 58(6):939-41. PubMed ID: 4615788
    [No Abstract]   [Full Text] [Related]  

  • 10. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.
    Ingle JN; Suman VJ; Mailliard JA; Kugler JW; Krook JE; Michalak JC; Pisansky TM; Wold LE; Donohue JH; Goetz MP; Perez EA
    Breast Cancer Res Treat; 2006 Jul; 98(2):217-22. PubMed ID: 16538529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen and fluoxymesterone in advanced breast cancer: a controlled clinical trial.
    Westerberg H
    Cancer Treat Rep; 1980 Jan; 64(1):117-21. PubMed ID: 6991101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ataxia caused by fluoxymesterone therapy in breast cancer.
    Agrawal BL
    Arch Intern Med; 1981 Jun; 141(7):958-9. PubMed ID: 7235823
    [No Abstract]   [Full Text] [Related]  

  • 13. An evaluation of adrenalectomy and androgen in disseminated mammary carcinoma.
    Dao TL; Nemoto T
    Surg Gynecol Obstet; 1965 Dec; 121(6):1257-62. PubMed ID: 4158865
    [No Abstract]   [Full Text] [Related]  

  • 14. The tamoxifen trial - a double-blind comparison with stilboestrol in postmenopausal women with advanced breast cancer.
    Stewart HJ; Forrest AP; Gunn JM; Hamilton T; Langlands AO; McFadyen IJ; Roberts MM
    Eur J Cancer (1965); 1980; Suppl 1():83-8. PubMed ID: 7032945
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of chemo-endocrine therapy in recurrent breast cancer].
    Kawaura Y; Hashizume Y; Ishida K; Katada S; Hirano M; Yamada T; Iwa T
    Nihon Gan Chiryo Gakkai Shi; 1986 Feb; 21(1):68-72. PubMed ID: 3701167
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effects of the therapy combined with oophorectomy for the advanced breast cancer].
    Shinoda M; Oka T
    Gan No Rinsho; 1971; 17(9):670-5. PubMed ID: 5165861
    [No Abstract]   [Full Text] [Related]  

  • 17. [Neurological manifestations in treatment with androgenic hormones].
    in 't Veld CJ; Bieger R; Mosmans PC
    Ned Tijdschr Geneeskd; 1983 Jun; 127(26):1154-5. PubMed ID: 6888577
    [No Abstract]   [Full Text] [Related]  

  • 18. Fluoxymesterone as third line endocrine therapy for advanced breast cancer. A phase II trial of the Piedmont Oncology Association.
    Schifeling DJ; Jackson DV; Zekan PJ; Muss HB
    Am J Clin Oncol; 1992 Jun; 15(3):233-5. PubMed ID: 1590276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation of estrogen-androgen combination in advanced breast cancer.
    Haines CR; Wallace HJ; Nevinny HB; Hall TC
    Am J Surg; 1969 Apr; 117(4):589-94. PubMed ID: 4891037
    [No Abstract]   [Full Text] [Related]  

  • 20. [Role of supporting therapy of Juzentaiho-to (JTT) in advanced breast cancer patients].
    Adachi I; Watanabe T
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1538-43. PubMed ID: 2730051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.